Adamis Pharmaceuticals Message Board

What's the Strategy in the U.S. for Neovasc's Reducer?

6 months ago

Neovasc (Nasdaq: NVCN) is a medical device company primarily known for Reducer, which is a minimally invasive device that helps treat patients with refractory angina. The device has been approved in Europe

Adamis Pharmaceuticals Patent Settlement

7 months ago

Adamas finally resolved the patent litigation and settled with Sandoz regarding their Abbreviated New Drug Application seeking approval by the FDA to market a generic version of GOCOVRI Extended Release Capsules.

“I am pleased to announce this settlement agreement with Sandoz, which demonstrates the strength of Adamas’ intellectual property and provides both parties with certainty,” said Neil F. McFarlane, Chief Executive Officer of Adamas Pharmaceuticals, Inc. “With the launch of GOCOVR…

Adamis Pharmaceuticals ZIMHI

9 months ago

Dr. Dennis J. Carlo, President and CEO of Adamis, stated, “Obviously, we are very surprised and disappointed. With a growing number of fatal overdoses as a result of more potent opioids like fentanyl, we believe there is an obvious need for higher dose forms of naloxone and we remain committed to bringing ZIMHI to the market. We believe the comments and recommendations stated in the CRL are manageable and plan to fully cooperate with the FDA. We remain committed to this product and our mission…